Welcome to our dedicated page for Pacira Biosciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pacira BioSciences, Inc. (NASDAQ: PCRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. Pacira is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its filings give detailed insight into how it manages product commercialization, manufacturing, financing and governance.
Pacira’s current reports on Form 8‑K cover topics such as quarterly financial results, workforce reductions tied to manufacturing efficiencies for EXPAREL, and a senior secured revolving credit facility used to refinance prior indebtedness and support working capital. One 8‑K describes the company’s investment in large-scale manufacturing suites in San Diego, California, and Swindon, United Kingdom, and the decision to decommission an earlier 45‑liter batch suite, while another outlines the terms of its credit agreement with lenders.
Investors reviewing Pacira’s filings typically focus on annual reports on Form 10‑K and quarterly reports on Form 10‑Q for information about its commercial products—EXPAREL, ZILRETTA and iovera°—and its clinical-stage gene therapy candidate PCRX-201. These filings generally discuss revenue composition, research and development activities, manufacturing capacity, risk factors and intellectual property, including patent protection for EXPAREL described in company press releases.
Forms 8‑K also document material events such as share repurchase authorizations, inducement equity grants under the company’s inducement plan, credit facility amendments and other significant corporate actions. For users interested in insider activity, Forms 3, 4 and 5 provide data on transactions by directors, officers and major shareholders, while proxy statements explain executive compensation and board matters.
On Stock Titan, AI-generated summaries help explain lengthy filings, highlight key changes from prior periods and surface items that may affect Pacira’s financial position or strategy. Real-time updates from EDGAR ensure that new 10‑K, 10‑Q, 8‑K and Form 4 filings for PCRX are quickly available, allowing investors to track developments in Pacira’s non-opioid pain portfolio, manufacturing initiatives and capital structure without reading every page manually.
DOMA Perpetual Capital Management LLC, which says it beneficially owns approximately 6.83% of Pacira BioSciences, Inc. common stock, plans to run a dissident slate of three independent director candidates at Pacira’s 2026 annual shareholder meeting. DOMA states that Pacira’s board should pursue an immediate sale of the company and criticizes current executive compensation and general spending as “exorbitant and unmerited,” while also questioning whether the board has provided appropriate fiduciary oversight.
DOMA and affiliated entities, including DOMA Perpetual LO Equity Master Fund LP, DOMA Perpetual Partners GP LLC, Reliability LLC and Pedro Escudero, intend to solicit votes using a WHITE proxy card and will file a detailed proxy statement with the SEC. The group collectively may be deemed to beneficially own several million Pacira shares through various entities, and it urges Pacira stockholders to review its forthcoming proxy materials when available.
Pacira BioSciences, Inc. filed a current report stating that it has issued a press release with its preliminary, unaudited revenue for the fourth quarter and full year ended December 31, 2025. The company is sharing an early view of its 2025 revenue performance before final audited results are available.
The press release, dated January 8, 2026, is included as Exhibit 99.1. Pacira notes that this revenue information is being furnished rather than filed under securities laws, which limits how it is treated for certain liability and incorporation-by-reference purposes.
Pacira BioSciences Chief Medical Officer Jonathan Slonin reported an automatic share withholding related to equity compensation. On January 2, 2026, 381 shares of Pacira common stock were withheld at $24.46 per share to cover tax obligations when a restricted stock unit award vested. After this withholding, Slonin beneficially owned 178,523.175 shares of Pacira common stock, which includes 537.166 shares acquired through the company’s employee stock purchase plan in December 2025. This filing reflects routine tax and ownership reporting rather than an open-market trade.
Pacira BioSciences Senior Vice President of Finance Lauren Riker reported two stock transactions in early January 2026. On January 2, 2026, 159 shares of Pacira common stock were withheld by the company at $24.46 per share to cover tax obligations when a restricted stock unit award vested. On January 5, 2026, Riker sold 1,416 shares of common stock at a price of $24.24 per share under a pre‑established Rule 10b5‑1 trading plan. After these transactions, Riker directly owned 59,064.242 shares of Pacira common stock, which includes 1,075.242 shares acquired through the company’s employee stock purchase plan in December 2025.
Pacira BioSciences Chief Commercial Officer Brendan Teehan acquired additional company stock through an employee purchase plan. On 12/31/2025, he obtained 402.268 shares of Pacira common stock at a price of $10.763 per share under the issuer's employee stock purchase plan.
After this transaction, Teehan directly beneficially owned a total of 54,402.268 shares of Pacira common stock, reflecting his ongoing equity participation as an executive officer.
Pacira BioSciences, Inc. (PCRX) reported an insider stock sale by its Chief Medical Officer. On 11/17/2025, the officer sold 3,960 shares of Pacira common stock at a price of $24.09 per share, according to a Form 4 filing. After this transaction, the officer directly beneficially owned 178,367.009 shares of Pacira common stock.
The filing states that this sale was carried out under a Rule 10b5-1 trading plan, which is a pre-arranged plan for buying or selling stock that is intended to comply with securities regulations and provide an affirmative defense against insider trading claims.
Pacira BioSciences (PCRX) disclosed that its Chief Financial Officer sold 12,060 shares of common stock at $22.09 per share on 11/10/2025.
The transaction was executed under a Rule 10b5-1 trading plan. After this sale, the CFO beneficially owns 56,250 shares, held directly.
Pacira BioSciences reported quarterly results for the period ended September 30, 2025. Total revenues were $179.5 million, up from $168.6 million a year ago, driven by net product sales of $178.0 million. EXPAREL led with $139.9 million, followed by ZILRETTA at $29.0 million and iovera° at $6.5 million.
The company posted net income of $5.4 million versus a prior-year loss that included a goodwill impairment. Operating expenses fell sharply year over year, with no goodwill impairment this quarter but including a $25.9 million impairment to indefinite‑lived IPR&D tied to ZILRETTA shoulder OA. Nine‑month cash from operations was $108.3 million.
Pacira reshaped its balance sheet: it repaid $202.5 million of 2025 convertible notes at maturity, terminated its Term Loan A, and established a $300.0 million revolving credit facility, with $96.0 million outstanding at quarter‑end. Cash and cash equivalents were $147.6 million and short‑term investments $98.7 million. The company also repurchased $50.0 million of stock in the quarter, bringing year‑to‑date repurchases to $100.4 million; shares outstanding were 42,965,902 as of September 30, 2025.
Pacira BioSciences, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The full text is included as Exhibit 99.1.
The company states the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed filed under the Exchange Act. PCRX common stock trades on the Nasdaq Global Select Market.
Pacira BioSciences (PCRX) reported an insider tax-withholding transaction by its CFO. On 10/31/2025, 6,690 shares of common stock were withheld by the company at $21.38 to cover taxes due upon restricted stock unit vesting.
Following the withholding, the officer directly beneficially owns 68,310 shares. The filing lists the transaction code as F, which denotes shares withheld for tax obligations related to equity awards.